ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

ClinicalTrials.gov ID: NCT03397264

Public ClinicalTrials.gov record NCT03397264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

Study identification

NCT ID
NCT03397264
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Opthea Limited
Industry
Enrollment
153 participants

Conditions and interventions

Interventions

  • Aflibercept Biological
  • OPT-302 Biological
  • Sham intravitreal injection Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 15, 2018
Primary completion
Mar 25, 2020
Completion
Jun 10, 2020
Last update posted
Apr 21, 2025

2018 – 2020

United States locations

U.S. sites
34
U.S. states
17
U.S. cities
34
Facility City State ZIP Site status
Opthea Investigational Site Phoenix Arizona 85014
Opthea Investigational Site Bakersfield California 93309
Opthea Investigational Site Beverly Hills California 90211
Opthea Investigational Site Redlands California 92374
Opthea Investigational Site Sacramento California 95819
Opthea Investigational Site Santa Ana California 92705
Opthea Investigational Site Colorado Springs Colorado 30909
Opthea Investigational Site Boynton Beach Florida 33426
Opthea Investigational Site Fort Myers Florida 33912
Opthea Investigational Site Melbourne Florida 32901
Opthea Investigational Site Pensacola Florida 32503
Opthea Investigational Site St. Petersburg Florida 33711
Opthea Investigational Site Augusta Georgia 30909
Opthea Investigational Site Indianapolis Indiana 46290
Opthea Investigational Site Des Moines Iowa 50266
Opthea Investigational Site Wichita Kansas 67214
Opthea Investigational Site Hagerstown Maryland 21740
Opthea Investigational Site Las Vegas Nevada 89144
Opthea Investigational Site Reno Nevada 89502
Opthea Investigational Site Asheville North Carolina 28803
Opthea Investigational Site Charlotte North Carolina 28210
Opthea Investigational Site Youngstown Ohio 92705
Opthea Investigational Site Portland Oregon 97213
Opthea Investigational Site Charleston South Carolina 29414
Opthea Investigational Site West Columbia South Carolina 29169
Opthea Investigational Site Rapid City South Dakota 57701
Opthea Investigational Site Germantown Tennessee 38138
Opthea Investigational Site Abilene Texas 79606
Opthea Investigational Site Arlington Texas 76012
Opthea Investigational Site Austin Texas 78705
Opthea Investigational Site Houston Texas 77030
Opthea Investigational Site McAllen Texas 78503
Opthea Investigational Site San Antonio Texas 78240
Opthea Investigational Site Willow Park Texas 76087

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03397264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03397264 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →